The North Dakota Cancer Coalition (NDCC) board of directors invites you to join us at the North Dakota Cancer Coalition and North Dakota Colorectal Cancer Roundtable (NDCCRT) annual meetings, June 24-25, at the North Dakota Heritage Center Museum in Bismark, ND.
Our annual meetings include educational opportunities for physicians, nurses, industry representatives, state and community partners, and cancer survivors from across North Dakota. Our membership includes healthcare professionals across all practice settings. The specific goals of our annual meetings are to facilitate collaboration and knowledge sharing and spur engagement among members, and for each person to leave the meetings in action. To help meet these goals, we ask you and your company for support of our efforts.
The NDCC and NDCCRT annual meetings are offering vendor space for the first time this year and will encourage all of our participants to visit the exhibitor booths to learn more about all of our sponsors. The vendor exhibit area will be separate space from the educational area. We expect approximately 150 attendees over the two days.
NDCC Annual Meeting Objectives
- Facilitate Networking and Collaboration: Learners will connect with peers, share experiences, and foster collaborations through networking activities and breaks.
- Update on Recent Activities: Learners will understand and discuss recent activities and achievements of various action teams, including Breast Cancer, Colorectal Cancer, and Skin Cancer/Sun Safety.
- Promote Awareness and Education: Learners will gain insights from survivor stories and educational materials to enhance their awareness and knowledge about cancer prevention and treatment.
- Discuss Future Plans: Learners will comprehend and contribute to discussions on the ND Cancer Plan 2025 – 2035, aligning efforts and setting future goals.
- Highlight Research and Innovations: Learners will identify barriers and will be able to apply recent research developments and innovative approaches in cancer prevention and treatment through expert presentations.
- Recognize Contributions: Learners will acknowledge and celebrate the contributions of “Turn ND Blue” initiative winners to cancer prevention efforts.
- Panel Discussions: Learners will engage in and implement strategies from panel presentations discussing various cancer projects and initiatives, facilitating knowledge sharing and discussion.
NDCCRT Annual Meeting Objectives
- Enhance Screening Implementation: Learners will discuss and demonstrate tools and measures for implementing follow-up colorectal cancer (CRC) screening in practice.
- Promote Rural Cancer Care: Learners will address and strategize for the unique challenges of providing colorectal cancer care in rural areas of North Dakota.
- Share Personal Stories: Learners will understand the human impact of colorectal cancer and the importance of screening and early detection through personal stories like Rachel’s Story.
- Facilitate Knowledge Exchange: Learners will gain insights and best practices from experts through presentations and panel discussions.
- Interactive Learning: Learners will participate in facilitated activities to reinforce learning and encourage active engagement.
Registration
Registration is now closed for the 2025 Annual Meetings. You may still Become a Member and join us at the meetings!
If you’re already a member, please log in instead.
The appearance of hyperlinks does not constitute endorsement by the ND Cancer Coalition of this website, information, products or services contained therein.
Women’s Way
Women’s Way is North Dakota’s Breast and Cervical Cancer Early Detection Program, providing eligible women with access to free or low‑cost breast and cervical cancer screenings, diagnostic services, and patient navigation to help overcome barriers to care. The program is administered by North Dakota Health and Human Services in partnership with local public health agencies statewide.
Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Pharmacosmos Therapeutics
Pharmacosmos Therapeutics specializes in iron deficiency therapies, developing treatments to improve outcomes for patients with chronic disease-related iron deficiency.
PharmaEssentia
PharmaEssentia is a biopharmaceutical company committed to advancing treatments for hematologic disorders and oncology through innovative biologic therapies.
GSK
GSK is a global biopharma company focused on vaccines, specialty medicines, and general medicines to prevent and treat disease and improve quality of life.
Gilead Sciences
Gilead Sciences is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases, including cancer, HIV, liver disease, and inflammation.
Bismarck Cancer Center
Bismarck Cancer Center provides comprehensive oncology care, offering advanced cancer treatment services close to home for patients in the region.
Syndax
Syndax is a clinical-stage biopharmaceutical company developing epigenetic therapies to treat cancer, focused on addressing areas of high unmet medical need.
Tempus AI
AI-enabled precision medicine: Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.
Guardant Health
Guardant Health is a precision oncology company developing blood‑based and tissue genomic testing solutions to help detect cancer early, guide treatment decisions, and improve patient outcomes.
Deciphera
Deciphera is a biopharmaceutical company focused on discovering and developing targeted therapies for patients with cancer, particularly those with difficult-to-treat tumors.
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development and delivery of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast, lung and gastric cancer, tenosynovial giant cell tumor and iron deficiency anemia. Visit us at www.daiichisankyo.us.
The appearance of hyperlinks does not constitute endorsement by the ND Cancer Coalition of this website, information, products or services contained therein.
Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development and delivery of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast, lung and gastric cancer, tenosynovial giant cell tumor and iron deficiency anemia. Visit us at www.daiichisankyo.us.
Questions? Please contact us or send an email to contact@ndcancercoalition.org.
